VIPAS39

Across TCGA pan-cancer cohorts, VIPAS39 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated VIPAS39 data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher VIPAS39 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated VIPAS39 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where VIPAS39 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.996	0.701	.008	8	view →
HNSC	OS	Median	II,III,IV	0.816	0.657	.030	8	view →
CCRCC	DFS	Median	All	0.848	0.624	.006	5	view →
LSCC	DFS	Median	II,III,IV	0.444	0.883	.030	3	view →
LUAD	OS	Median	III,IV	0.235	0.705	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

VIPAS39–PDAC (OS)

Open the PDAC breakdown →